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Original Article

Engineering of GlcNAc-1-Phosphotransferase for
Production of Highly Phosphorylated Lysosomal
Enzymes for Enzyme Replacement Therapy
Lin Liu,1 Wang-Sik Lee,1 Balraj Doray,1 and Stuart Kornfeld1
1Department

of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

Several lysosomal enzymes currently used for enzyme replacement therapy in patients with lysosomal storage diseases
contain very low levels of mannose 6-phosphate, limiting their
uptake via mannose 6-phosphate receptors on the surface of the
deﬁcient cells. These enzymes are produced at high levels by
mammalian cells and depend on endogenous GlcNAc-1-phosphotransferase a/b precursor to phosphorylate the mannose
residues on their glycan chains. We show that co-expression
of an engineered truncated GlcNAc-1-phosphotransferase
a/b precursor and the lysosomal enzyme of interest in the producing cells resulted in markedly increased phosphorylation
and cellular uptake of the secreted lysosomal enzyme. This
method also results in the production of highly phosphorylated
acid b-glucocerebrosidase, a lysosomal enzyme that normally
has just trace amounts of this modiﬁcation.

INTRODUCTION
Enzyme replacement therapy (ERT) is currently the major form of
treatment for a number of lysosomal storage diseases, although its efﬁcacy varies among the individual disorders.1 Most of these inherited
disorders arise from the lack of activity of a single lysosomal enzyme,
which leads to the accumulation of the material normally degraded by
the enzyme. The build-up of the storage material in the lysosome
eventually results in cell and organ dysfunction. The goal of ERT is
to introduce sufﬁcient amounts of normal enzyme into the lysosomes
of the deﬁcient cells to clear the storage material and restore lysosome
function. This form of therapy was ﬁrst used in patients with type 1
Gaucher disease, who lack acid b-glucocerebrosidase (GBA) activity
and accumulate glucosylceramide primarily in macrophage type
cells.2 The replacement enzyme, containing N-linked glycans with
terminal mannose residues, is infused intravenously and taken up
by macrophages via cell surface mannose receptors. The endocytosed
enzyme is then transported via endosomes to lysosomes, where it
functions with good clinical results in this disorder.3
Because most cell types lack mannose receptors, the replacement enzymes used to treat lysosomal storage disorders that involve cell types
other than macrophages use binding to the cation-independent
mannose 6-phosphate receptor (CI-MPR) at the cell surface for subsequent delivery to lysosomes. In this regard, studies of a mouse
model of Gaucher disease have produced evidence for the involve-

ment of multiple cell lineages other than macrophages in the pathophysiology of this disorder, particularly osteoblasts, dendritic cells,
and T cells.4 Therefore, a therapy that included these cell types may
be of clinical beneﬁt in this disorder.
The enzymes used for ERT are puriﬁed from the secretions of
mammalian cells, mostly Chinese hamster ovary cells, engineered
to produce high levels of the enzyme of interest. The feasibility of
this approach is dependent upon the ability of the endogenous
GlcNAc-1-phosphotransferase to phosphorylate mannose residues
of the N-glycans of the expressed lysosomal enzyme. Some of the
replacement enzymes produced by this technique are highly phosphorylated and bind well to the CI-MPR. Others, however, are poorly
phosphorylated, limiting their effectiveness in ERT. This includes the
Pompe disease enzyme (acid a-glucosidase [GAA]) and the alphamannosidosis enzyme (lysosomal acid a-mannosidase [LAMAN]).5,6
In addition, the GBA currently used in the treatment of Gaucher disease contains a very low level of Man-6-P.7
We considered two possibilities for why GAA and LAMAN are
poorly phosphorylated. First, the activity of the endogenous
GlcNAc-1-phosphotransferase in the producing cells may be insufﬁcient to effectively phosphorylate the high levels of these enzymes
being synthesized. If this were the case, co-transfection of GlcNAc1-phosphotransferase with the lysosomal enzyme would be expected
to enhance phosphorylation. One potential limitation to this
approach is that overexpression of wild-type (WT) GlcNAc-1-phosphotransferase in mammalian cells can result in a portion of the
expressed enzyme remaining inactive because of lack of proteolytic
cleavage by the Site-1 protease (S1P), which is essential for catalytic
activation of the protein.8 A second possibility is that these two lysosomal enzymes are poor substrates for WT GlcNAc-1-phosphotransferase compared with other lysosomal enzymes. Evidence that this is
the case with GAA has been presented.9 GBA differs from the other

Received 25 January 2017; accepted 22 March 2017;
http://dx.doi.org/10.1016/j.omtm.2017.03.006.
Correspondence: Stuart Kornfeld, Hematology Division, Department of Internal
Medicine, Campus Box 8125, Washington University School of Medicine, 660
South Euclid Avenue, St. Louis, MO 63110, USA.
E-mail: skornfel@dom.wustl.edu

Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017 ª 2017
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

59

Molecular Therapy: Methods & Clinical Development

Figure 1. Expression of a Minimal GlcNAc-1Phosphotransferase and Analysis of Enzyme
Activity
(A) Schematic of WT and the various a/b precursor
deletion constructs expressed in GNPTAB / HeLa cells.
The four regions in lime comprise the catalytic Stealth
domain, while the two Notch modules (N1 and N2) and
the DNA methyl-transferase-associated protein (DMAP)
interaction domain are involved in lysosomal enzyme
recognition. In S1-D and S1-S3, the 236 aa human
spacer-1 (S1) sequence was replaced with 29 aa of the
D. discoideum sequence, in addition to removal of N1
through most of spacer-3 (S3) up to the K928 cleavage
site (asterisk). (B) Immunoblot of WT a/b precursor and
the deletion mutants expressed in GNPTAB / HeLa
cells. The indicated amount of each cell extract was
loaded, and the a/b precursor and b subunits were detected with an anti-V5 antibody. (C) Catalytic activity of
WT a/b precursor and the deletion mutants toward aMM
using equal amounts of whole-cell extracts. The vectoronly transfected GNPTAB / HeLa cell extract served as
a control, and WT value was set to 100% after subtraction
of vector-only background. (D and E) Transfection of
GNPTAB / HeLa cells with either WT a/b precursor or
the various deletion mutant cDNAs. The degree of
phosphorylation mediated WT or mutant proteins was
determined by binding of three endogenous lysosomal
enzymes to CI-MPR-affinity beads. Bound material was
assayed for activity, and values obtained with cells
transfected with WT a/b are set to 100%. (F) Mannose
phosphorylation of total soluble proteins was determined
by transfecting GNPTAB / HeLa cells with WT a/b
precursor or the indicated deletion mutant cDNAs,
followed by [2-3H]mannose labeling. Values shown are calculated as the percentage of counts recovered with the CI-MPR affinity beads as a fraction of the total counts in the
phosphotungstic acid precipitate. The background value of 0.8 ± 0.3% was subtracted to yield the final depicted vales. *p < 0.05, **p < 0.01. (G) Immunoblot analysis of
GNPTAB / HeLa cells co-transfected with the expression plasmids for the indicated proteins along with empty vector, WT a/b precursor, or the indicated deletion mutant
cDNAs. Cell lysates were incubated with CI-MPR-affinity beads, and the binding of the various proteins was determined by probing the blots with the following antibodies:
anti-HA for Renin, anti-myc for PoFut2, anti-Strep tag for the vWF A1A2A3 domains, and antibodies generated against the native protein for GP, Lamp1, and Lamp2. Error
bars represent mean ± SD.

lysosomal enzymes in that it is known to be transported to lysosomes
by a Man-6-P-independent pathway.10 This fact, plus its very low
content of Man-6-P, has led to the conclusion that it is not a substrate
for GlcNAc-1-phosphotransferase.
During the course of studies to understand the roles of the various
domains of the a/b subunits of GlcNAc-1-phosphotransferase, we
engineered a modiﬁed enzyme that bypasses the requirement for proteolytic cleavage, is highly expressed and has good activity toward a
panel of endogenous lysosomal enzymes. We then compared the ability of the WT and modiﬁed GlcNAc-1-phosphotransferase to act on a
number of poorly phosphorylated lysosomal enzymes when co-transfected into cells. Our ﬁndings document that it is possible to substantially enhance the phosphorylation of lysosomal enzymes, including
GBA, that are poor substrates for GlcNAc-1-phosphotransferase
using our modiﬁed GlcNAc-1-phosphotransferase. Acid hydrolases
synthesized by this procedure display increased binding to
Man-6-P receptors and enhanced uptake by target cells compared
with the enzymes produced by the current procedure.
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RESULTS
Generation of a Highly Active Variant of GlcNAc-1Phosphotransferase

GlcNAc-1-phosphotransferase is an a2b2g2 hexamer encoded by two
genes (GNPTAB and GNPTG). We have reported that the a/b subunits are able to phosphorylate most lysosomal enzymes in the
absence of g.11 Therefore, we used a construct encoding only the
a/b precursor as the starting source of mannose phosphorylating
activity. Proteolytic cleavage of this precursor at K928 to give rise
to the a and b subunits is mediated by the Site-1 protease in the Golgi,
and this process is essential for catalytic competency of the protein.8,9
The a subunit contains two Notch modules and a DNA methyltransferase-associated protein (DMAP) interaction domain that mediate
the speciﬁc recognition of protein determinants on the lysosomal
enzyme substrates (Figure 1A).12 In addition, there are four so-called
spacer domains in the a/b precursor whose functions are beginning to
be elucidated. Thus, we have reported that spacer-1 (residues 86–322)
determines the site of cleavage of the a/b precursor and serves to
limit the phosphorylation of non-lysosomal glycoproteins,13 whereas
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spacer-2 contains the g-subunit binding site.12,14 Besides these domains, the a and b subunits also harbor four Stealth domains that
together form the catalytic core of the protein. The Stealth domains
of all eukaryotic GlcNAc-1-phosphotransferases are highly conserved
and resemble sequences within bacterial proteins that encode sugarphosphate transferases involved in cell wall polysaccharide biosynthesis.15 In contrast to the mammalian enzymes, however, the
bacterial proteins such as the N. meningitidis GlcNAc-1-phosphotransferase (Figure S1) lack the other domains, with no evidence
that proteolytic cleavage is necessary for catalytic activation.16
Thus, we asked if it was possible to engineer a human GlcNAc-1phosphotransferase that is not cleaved but retained high catalytic
activity toward the N-linked glycans of lysosomal enzymes.
We have previously reported that a construct (N1-D; Figure 1A) lacking the region from the Notch1 module to the end of DMAP (residues
438–819) is well expressed and has good catalytic activity toward the
simple sugar a-methylmannoside (aMM) but is unable to phosphorylate lysosomal enzymes.12 When deletion of this region was combined with removal of spacer-1 (construct S1-D), the expressed
protein (Figure 1B, lane 5) had similar activity as N1-D toward
aMM but slightly greater phosphorylation activity toward the lysosomal enzyme panel (Figures 1C and 1D), despite only a small
amount of the b subunit product resulting from this construct (Figure 1B, compare lanes 4 and 5). This is in agreement with our recent
study that upon removal of spacer-1, the uncleaved a/b precursor retains some catalytic activity.13 To determine if it was possible to
bypass the requirement for cleavage altogether, construct N1-S3
was made, which extended the deletion from Notch1 up to the
Site-1 protease cleavage site in spacer-3 (residues 438–928). This
construct, which remained a single-chain molecule, was very highly
expressed (Figure 1B, lane 6), properly localized to the Golgi (Figure S2), and was 17-fold more active toward aMM than observed
with WT a/b (Figure 1C). However, it only phosphorylated the panel
of lysosomal enzymes about 30%–40% as well as the WT transferase
(Figure 1E). We also tested the ability of N1-S3 and WT enzyme to
phosphorylate the total cellular pool of soluble glycoproteins, which
would include proteins other than lysosomal enzymes. For this experiment, cells transfected with either the WT or the modiﬁed construct
were labeled with [2-3H]mannose for 2 hr. The cells were then lysed,
and following removal of the membrane fraction by high-speed
centrifugation, the supernatants were incubated with CI-MPR beads
to bind the Man-6-P-containing proteins, and the percentage of total
counts bound was determined. As shown in Figure 1F, both constructs phosphorylated about 2.6% of the total soluble glycoprotein
pool. Because N1-S3 had less activity toward lysosomal enzymes
than WT, this result indicated that it acted upon non-lysosomal glycoproteins to a greater extent than does the WT enzymes.
The ﬁnal construct (S1-S3) had spacer-1 deleted along with the region
from Notch1 to the cleavage site in spacer-3 (Figure 1A). This
construct, like the N1-S3, was expressed at a much higher level
than the WT construct (Figure 1B, lane 7), localized to the Golgi (Figure S2), and displayed a 21-fold increase in catalytic activity toward

aMM over WT a/b (Figure 1C). It also phosphorylated the lysosomal
enzyme panel better than observed with N1-S3, ranging from 56%–
117% of WT level (Figure 1E). Strikingly, we noted that S1-S3 phosphorylated the total pool of cellular soluble glycoproteins 3-fold
greater than N1-S3 and the WT enzyme, consistent with increased
phosphorylation of lysosomal enzymes that are poorly phosphorylated by the WT enzyme as well as an enhanced ability to phosphorylate non-lysosomal glycoproteins (Figure 1F). To test the latter
possibility, we determined the ability of the various constructs
to phosphorylate a panel of non-lysosomal glycoproteins, two of
which were known to be weak substrates of WT GlcNAc-1-phosphotransferase, namely, Renin and protein O-fucosyltransferase 2
(PoFut2).17,18 Phosphorylation was determined by binding to CIMPR beads followed by western blotting to detect the proteins. As
shown in Figure 1G, the S1-S3 construct phosphorylated Renin,
PoFut2, glycopepsinogen (GP), and the von Willebrand factor
(vWF) A1A2A3 domain, whereas the WT construct only phosphorylated Renin weakly in this assay. The N1-S3 construct acted on these
proteins as well but to a lesser degree than S1-S3. None of these constructs phosphorylated the membrane glycoproteins, Lamp1 and
Lamp2.
In an attempt to further reduce human GlcNAc-1-phosphotransferase to resemble the N. meningitidis enzyme (Figure S1), a series of
deletions within spacer-4 were generated. However, none of these
mutants displayed enzyme activity toward aMM (data not shown).
Co-transfection of GlcNAc-1-Phosphotransferase with
Lysosomal Enzymes Enhances Phosphorylation

On the basis of the above ﬁndings, we selected construct S1-S3 along
with the WT a/b precursor construct to co-transfect with plasmids
encoding the three poorly phosphorylated lysosomal enzymes
(LAMAN, GAA, and GBA) and GLA as a control for a well-phosphorylated enzyme. In the initial experiment, the constructs were
co-expressed in GNPTAB / HeLa cells, followed by incubation
with [2-3H]mannose to label the N-linked glycans of the lysosomal
enzymes. The media was collected and the secreted proteins were
immunoprecipitated and analyzed for their content of glycans containing one or two Man-6-P residues. As shown in Figure 2, the S1S3 construct produced 2.1- to 4.9-fold greater phosphorylation of
the glycans present on the panel of lysosomal enzymes that were
co-expressed with this truncated a/b precursor relative to WT.
Next we co-transfected either Expi293 cells or mouse D9 L cells (lacking the CI-MPR) with the same plasmids and collected the media after
48–72 hr to use as a source of secreted lysosomal enzymes for receptor
binding and cell uptake experiments. As a control for phosphorylation mediated by the endogenous GlcNAc-1-phosphotransferase,
cells were transfected with plasmids encoding the lysosomal enzymes
but not with the cDNAs for the a/b precursors. A representative Coomassie blue-stained SDS gel of the media from Expi293 cells is shown
in Figure S3. In all instances, the enzyme secreted by cells co-transfected with the S1-S3 construct bound to the CI-MPR-beads to a
much greater extent than observed with the lysosomal enzymes
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Figure 2. Phosphorylation of Lysosomal Enzymes by S1-S3
GNPTAB / HeLa cells were co-transfected with either WT or S1-S3 a/b precursor
cDNAs, along with expression plasmids for four lysosomal enzymes. Forty-eight
hours post-transfection, cells were labeled for 2 hr with [2-3H]-mannose, followed
by immunoprecipitation of the proteins secreted into the media and determination of
the percentage N-glycans containing one (1PM) or two (2PM) Man-6-P residues.
The absolute values of the percentage glycans phosphorylated are shown.
*p < 0.05, **p < 0.01. Error bars represent mean ± SD.

expressed alone in the cells (Figure 3). This is indicative of enhanced
phosphorylation. Further, with the exception of LAMAN, co-transfection with S1-S3 resulted in signiﬁcantly greater lysosomal enzyme
binding to the CI-MPR-beads than obtained with the WT enzyme.
The impact of the increased Man-6-P content of the various lysosomal enzymes on their uptake by HeLa cells is shown in Table 1.
In all four instances, the enzymes secreted by cells co-transfected
with the plasmid encoding the truncated a/b precursor were internalized many fold better than enzyme secreted by cells using only the
endogenous GlcNAc-1-phosphotransferase. Similar results were obtained with co-transfection of the WT a/b precursor with the exception of GAA, consistent the CI-MPR-bead binding results. Most of
the uptake was blocked by the presence of 5 mM Man-6-P in the
media, showing that the uptake is mediated by the CI-MPR. The results with LAMAN were particularly striking, with Man-6-P-inhibitable uptake being stimulated by 130- to 153-fold. It is also notable that
the GBA was internalized to a great extent in a Man-6-P-dependent
manner.

DISCUSSION
The ﬁndings presented here establish that phosphorylation of expressed lysosomal enzymes can be substantially increased by cotransfection with an engineered truncated a/b precursor of
GlcNAc-1-phosphotransferase and, in some instances, with the WT
a/b precursor. Importantly, the g subunit, encoded by a different
gene, is not required for this effect. This simpliﬁes construction of
the producing cells. The enhanced phosphorylation of the lysosomal
enzymes increases their binding to the CI-MPR and uptake by cells.
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Figure 3. Binding of Expressed Enzymes to CI-MPR
Expi293 cells or mouse D9 L-cells were co-transfected with expression plasmids for
the indicated lysosomal enzymes along with empty vector, WT a/b precursor, or the
S1-S3 mutant cDNA. D9 L-cells were used for generating GAA, while Expi293 cells
were used for the other lysosomal enzymes. Forty-eight to 72 hr post-transfection,
the media was collected, and aliquots were incubated with CI-MPR-beads to bind
the phosphorylated lysosomal enzymes. The percentage of each lysosomal enzyme
that bound to the CI-MPR-beads was determined as described in the Experimental
Procedures. Values obtained with cells transfected with the empty vector
(“endogenous”) represent the activity of the endogenous GlcNAc-1-phosphotransferase. *p < 0.05, **p < 0.01.

This effect even occurs with lysosomal enzymes such as GLA that
are well phosphorylated by the endogenous GlcNAc-1-phosphotransferase. But most important is the ﬁnding that this method enhances the phosphorylation and uptake of human LAMAN and
GAA, two lysosomal enzymes that are poorly phosphorylated by
endogenous GlcNAc-1-phosphotransferase. In addition, the production of GBA containing high levels of Man-6-P offers the opportunity
to restore enzyme activity to cell types in patients with Gaucher disease who lack the mannose receptor. This is of particular interest in
light of the reported ﬁndings in a mouse model of Gaucher disease
that cell types other than macrophages are dysfunctional in this disorder.4 The availability of highly phosphorylated GBA could potentially provide additional beneﬁt to the current therapy that is targeted
speciﬁcally to macrophages.
In conclusion, the methods described here have the potential to
signiﬁcantly improve the effectiveness of lysosomal enzymes in
ERT. In addition to providing better cell uptake, these preparations
may allow lower doses to be administered to patients, perhaps at
less frequent intervals. The method should be applicable to the production of phosphorylated lysosomal enzymes for other lysosomal
storage diseases that may be amenable to ERT.

MATERIALS AND METHODS
Cell Lines

Expi293 cells (Life Technologies) were grown in suspension in
Expi293 expression medium (Life Technologies). The GNPTAB /
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Table 1. Cell Uptake of Secreted Lysosomal Enzymes Phosphorylated by Endogenous GlcNAc-1-Phosphotransferase or Overexpressed WT Enzyme or the
S1-S3 Mutant
% Uptakea
Enzyme

LAMAN

GAA

GBA

GLA

PTase

Total Units Added

endogenous

670

WTa/b

359

S1-S3

530

endogenous

5.7

WTa/b

3.8

S1-S3

3.2

endogenous

2.7

WTa/b

2.3

S1-S3

2.8

endogenous

194

WTa/b

141

S1-S3

237

Man-6-P

M6PR Dependent
0.76 ± 0.23
0.62 ± 0.27

+

24.70 ± 1.34
3.20 ± 0.77

+

22.46 ± 4.07
+

4.30 ± 1.19

+

0.22 ± 0.42

+

0.44 ± 1.16

4.05 ± 0.46
3.31 ± 1.13
12.79 ± 0.90
2.99 ± 1.59

+

10.74 ± 1.94
5.65 ± 1.51

+

46.73 ± 4.00
9.37 ± 1.26

+

49.74 ± 11.53
8.67 ± 4.21

+

2.72 ± 0.91
+

1.00 ± 0.11

+

1.30 ± 0.13

9.53 ± 0.11
7.01 ± 0.69
0.95 ± 0.11

+

Fold Increase

0.14

21.5

153

18.2

130

3.8

2.9

0.8

9.8

2.6

5.1

37.4

7.3

41.1

8.0

1.7

8.2

4.8

6.1

3.5

One unit = 1 nmol 4-methylumbelliferone released per hour. Uptake experiments were performed in either the absence or the presence of 5 mM Man-6-P.
a
Percentage uptake per 200 mg cell protein in 24 hr.

HeLa cell line has been described in detail elsewhere.12 Parental and
GNPTAB / HeLa cells were maintained as a monolayer in DMEM
(Life Technologies) containing 0.11 g/L sodium pyruvate and
4.5 g/L glucose, supplemented with 10% (vol/vol) fetal bovine serum
(FBS) (Atlanta Biologicals), 100,000 U/L penicillin, 100 mg/L
streptomycin (Life Technologies), and 2 mM L-glutamine (Life
Technologies). The CI-MPR negative mouse D9 L-cell line has
been described.19 D9 L- cells were maintained as a monolayer in
a-MEM (Life Technologies) containing 100,000 U/L penicillin and
100 mg/L streptomycin (Life Technologies).
DNA Constructs

Human GNPTAB-V5/His 8 in pcDNA6 and the N1-D deletion
construct has been described.12 Constructs S1-D and S1-S3 were
generated in two steps as follows: in the ﬁrst step, the human
spacer-1 sequence was replaced with D. discoideum spacer-1 using
a 0.5 kb gBlocks gene fragment (IDT) in a two-stage overlap extension
PCR (OE-PCR). Nucleotides corresponding to amino acids 438–819

or 438–928 were subsequently removed in the second step to generate
S1-D and S1-S3, respectively. The construct N1-S3 was generated by
deleting nucleotides encoding amino acids 438–928 from the WT
construct. The LAMAN-myc-Flag cDNA was purchased from
Origene, while the GAA cDNA was a kind gift of Eline van Meel
(Leiden University). The GLA and GBA cDNAs were generously
provided by Amicus Therapeutics. A C-terminal myc-tag was
appended to the GBA and GAA c-DNA. The PoFut2-myc cDNA
was a gift from Robert Haltiwanger (University of Georgia. Athens,
GA). Renin-HA cDNA was purchased from Addgene (Cambridge,
MA), while the plasmid, vWF-A1A2A3-Strep-pCDNA6, was kindly
provided by Joshua Muia and J. Evan Sadler (Washington University
School of Medicine, St. Louis, MO).
Phosphotransferase Assay

Constructs encoding the WT and S1-S3 a/b precursors were expressed in GNPTAB / HeLa by transfection with Lipofectatime
3000 (Life Technologies) according to the manufacturer’s protocol.
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Forty-eight hours post-transfection, cells in six-well plates were harvested and lysed in 250 mL of buffer A (25 mM Tris-Cl [pH 7.2],
150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail).
Either10 mL (WT) or 2 mL (S1-S3) of cell extract was incubated in
buffer B (50 mM Tris-Cl [pH 7.4], 10 mM MgCl2, 10 mM MnCl2,
2 mg/mL BSA, 2 mM ATP) in the presence of 75 mM UDP-GlcNAc,
1 mCi UDP-[3H]GlcNAc, and 100 mM a-MM in a ﬁnal volume of
50 mL for 1 hr at 37 C. The reactions were stopped by the addition
of 1 mL of 2 mM EDTA [pH 8.0], and the samples were subjected
to QAE-Sephadex chromatography as previously described.11
Western Blotting

Proteins resolved by SDS-PAGE under reducing conditions were
transferred to nitrocellulose membrane and detected with antibodies
as described in the ﬁgure legends. The indicated amounts of wholecell extracts were loaded on the gels.
Immunofluorescence Microscopy

To visualize the subcellular localization of WT a/b and the S1-S3
mutant, the constructs were transfected into GNPTAB / HeLa cells
using Lipofectamine 3000 according to the manufacturer’s protocol.
Twenty-four hours post-transfection, the cells were ﬁxed with 4%
formaldehyde (Sigma-Aldrich) and the a/b subunits were detected
with mouse anti-V5 monoclonal antibody (Life Technologies). The
Golgi marker GOLPH4 was detected with rabbit anti-GOLPH4 polyclonal antibody (Abcam). The processed cells were mounted in
ProLong Gold antifade mounting medium (Life Technologies), and
the images were acquired with an LSM880 confocal microscope
(Carl Zeiss). Images were analyzed using ImageJ software (Fiji).
[2-3H]Mannose Labeling Experiments for Lysosomal Enzymes

Labeling experiments were performed with transfected GNPTAB /
HeLa cells as follows: 48 hr post-transfection, cells in 60 mm tissue
culture plates were incubated with 50–150 mCi of [2-3H]mannose
(Perkin Elmer) for 2 hr, followed by the addition of complete medium
containing 5 mM glucose, 5 mM mannose, and 10 mM NH4Cl to stop
mannose uptake and induce secretion. The cells were incubated for an
additional 3 hr before the medium was collected for analysis. Acid hydrolases secreted into the media were immunoprecipitated, and oligosaccharides isolated and analyzed essentially as described in detail
previously.20 Because the LAMAN, GAA, and GBA cDNAs contained
a C-terminal myc-tag, 20 mL anti-myc monoclonal antibody (Santa
Cruz Biotechnology) was pre-bound to 100 mL Protein G-agarosePLUS beads (Santa Cruz Biotechnology) prior to immunoprecipitation of these lysosomal hydrolases from the media. In the case of
GLA, the secreted enzyme was immunoprecipitated with Protein
G-agarose-PLUS beads pre-bound to anti-a-Gal antibody (Amicus
Therapeutics). Immunoprecipitated material was treated with Endo
H (NEB) and ﬁltered with Ultracel-10K (EMD Millipore). The ﬁltrate
containing the released neutral and phosphorylated high mannose
glycans was treated with mild acid to remove any N-acetylglucosamine residues still attached to the phosphate moieties and applied
to a QAE-column matrix to separate the oligosaccharides bearing
zero, one or two Man-6-P residues. The retentate containing Endo
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H-resistant complex oligosaccharides was treated with Pronase
(Roche Diagnostics) and fractionated on ConA-Sepharose 4B (GE
Healthcare). The [2-3H]-mannose content of the various fractions
was determined, and the percentage phosphorylation was calculated
as described.20
[2-3H]Mannose Labeling Experiments for Total Soluble
Glycoproteins

Labeling experiments were performed with transfected GNPTAB /
HeLa cells as follows: 48 hr post-transfection, cells in six-well plates
were incubated with 10 mCi of [2-3H]mannose (Perkin Elmer) for
2 hr. Following the 2 hr pulse, cells were rinsed twice with PBS
and harvested, then resuspended in detergent-free buffer containing
25 mM Tris-Cl (pH 7.2) and 150 mM NaCl at 4 C with a protease
inhibitor cocktail (Life Technologies). Cell were lysed by sonication,
then subjected to ultracentrifugation at 100,000  g for 1 hr to
separate the membrane proteins from the soluble fraction. One
hundred microliters of the soluble fraction was then incubated
with puriﬁed CI-MPR that was covalently conjugated to Cyanogen
bromide-activated-Sepharose 4B in order to pellet the mannosephosphorylated glycoproteins, while 10 mL of the soluble fraction
was precipitated by 1.5% phosphotungstic acid to obtain total
[2-3H]mannose label incorporation into the soluble proteins. This
method allowed the accurate quantiﬁcation of all the mannoselabeled glycoproteins that were phosphorylated by either WT or
mutant GlcNAc-1-PT.
Enzyme Production

Mouse D9 L-Cells were co-transfected with GAA cDNA, along with
empty vector, WT a/b precursor, or S1-S3 mutant. Expi293 cells were
co-transfected with LAMAN, GBA, or GLA cDNAs, along with either
empty vector, WT a/b precursor, or S1-S3 mutant. The media was
harvested after 2–3 days. For the production of GBA, 10 mM of compound AT3375 (Amicus Therapeutics) was added to the media to stabilize the secreted enzyme.
CI-MPR Affinity Chromatography and Lysosomal Enzyme
Assays

Soluble bovine CI-MPR was puriﬁed from FBS and covalently conjugated to Cyanogen bromide-activated-Sepharose 4B (Sigma-Aldrich)
as described.21 Aliquots of media from 2- to 3-day transfected
Expi293 cells or mouse D9 L-cells were diluted with buffer A
(25 mM Tris-Cl [pH 7.2], 150 mM NaCl, and 1% Triton X-100)
and incubated with the CI-MPR beads at 4 C for 1 hr to bind the
phosphorylated lysosomal enzymes. The beads were then sedimented,
washed with buffer A, and assayed for lysosomal enzyme activity as
described.12,22,23 The amount of the starting enzyme recovered on
the beads was calculated.
Cell Uptake of Lysosomal Enzymes

Parental HeLa cells were plated on a 12-well plate at approximately
80% density 1 day prior to the cell uptake experiment. Aliquots of
media containing each enzyme from the producing cells were added
to the parental HeLa cells in a ﬁnal volume of 500 mL. For competition
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experiments, Man-6-P was added to a ﬁnal concentration of 5 mM.
The cells were incubated with the media for 24 hr, and then the cells
and media were collected separately. Cells were rinsed twice with PBS
and then lysed in buffer A. The media and cell extracts were centrifuged at 20,000  g, and the supernatants were assayed for their content of lysosomal enzyme activity.
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